Search

中文 / English

Address: No. 35, Simiao Road, Daxing Biomedical Industrial Base, Zhongguancun Science Park, Daxing District, Beijing
 Copyright: Beijing Minhai Biological Technology Co., Ltd.   
Beijing ICP 10007676    Powered by  www.300.cn Beijing    Beijing Public Security No. 110115000037 Internet Drug Information Service Qualification Certificate (Beijing) Non-operating 20150173

Contact

Administrative Office: 010-59613600
Supplier consultation: 010-59613585
Recruitment: 010-59613633
Marketing: 010-59613639
Medical support: 010-59613669

Links:

>
>
>
R & D and innovation have achieved great results, making vaccines beneficial to the people

R & D and innovation have achieved great results, making vaccines beneficial to the people

Release time:
2020/07/10
Page view
Shenzhen Kangtai Biological Products Co., Ltd., the parent company of Beijing minhai Biotechnology Co., Ltd. (hereinafter referred to as Kangtai biological products), is a listed enterprise mainly engaged in the research and development, production and sales of biological vaccine products, with stock code of 300601. Headquartered in Shenzhen, the company has R & D centers and industrial bases in Shenzhen and Beijing. It is one of the major hepatitis B vaccine manufacturers in China. At present, the main products include recombinant hepatitis B vaccine (Saccharomyces cerevisiae), Haemophilus influenzae type b conjugate vaccine, measles rubella joint attenuated live vaccine, acellular diphtheria pertussis type B combined vaccine, 23 valent pneumococcal polysaccharide vaccine and so on. Shenzhen Special Zone Daily reported in detail.
 
Shenzhen is an international innovative city full of charm, power, vitality and innovation. Her prosperity is a concentrated portrayal of her pioneering and innovative spirit.
 
In 1988, it was in the fertile land of innovation that Shenzhen Kangtai Biological Products Co., Ltd., an enterprise that made outstanding contributions to the national immunization cause.
 
 
After more than 30 years of development, Kangtai biological has gradually become a "catcher" with strong R & D strength from the "successor" of foreign vaccine technology. For more than 30 years, Kangtai biological has been following the main theme of scientific and technological innovation, continuously increasing investment in vaccine technology research and development, and building a more solid barrier for protecting people's life and health.
 
Fang Sheng
 
Shouldering the mission
 
To undertake the "fire" of hepatitis B vaccine technology
 
In the early 1990s, hepatitis B virus still shrouded in people's head lingering shadow. According to the investigation results of the Ministry of health in 1992, 9.75% of the total population was positive for HBsAg, and the carrying rate of hepatitis B virus in children was as high as 9.67%. In order to deal with this problem, Merck transferred the technology of recombinant hepatitis B vaccine to China in 1989, and Kangtai biological took on the mission of undertaking the technology transfer of hepatitis B vaccine.
 
 
 
In 1991, Kangtai biological sent a special team to the United States on the other side of the ocean to receive technical training in Merck for one and a half years. In the face of the huge differences in unfamiliar environment, culture and living habits, the pioneers of Kangtai biology overcame many difficulties and successfully completed their mission, bringing the recombinant hepatitis B vaccine technology back to China.
 
 
 
Dare to be the first and develop diligently. For the sake of human health, the spirit of "Tuo Lu Niu" is reflected incisively and vividly in Kangtai people at the early stage of entrepreneurship. A person in charge of Kangtai biological Co., Ltd., who was involved in the whole process of technology introduction, said frankly: "at that time, everyone had a strong desire to help China's vaccine catch up with the world's advanced level as soon as possible. We are very proud to be able to participate in such projects and create such great social value. "
 
 
In 1994, with the unremitting efforts of the first generation of Kangtai people, the hepatitis B vaccine production workshop was successfully built, and 10 batches of qualified products were trial produced. This also marks the successful introduction of China's first genetic engineering vaccine project. In the following 20 years, Kangtai biological hepatitis B vaccine production capacity continued to expand, and the cumulative production and sales reached more than 1 billion doses, making more than 300 million people immune protection, reducing the risk of 40 million children infected with hepatitis B virus, and reducing public health expenditure of more than 160 billion yuan for the country.
 
 
At present, through the implementation of the comprehensive prevention and control strategy based on vaccination and combination of prevention and treatment, the HBsAg carrying rate of children under 5 years old in China has decreased from 9.7% in 1992 to 0.3% in 2014. According to the Chinese Health Statistics Yearbook (2019), the incidence rate of hepatitis B in China was 0.07% in 2018. During this period, Kangtai biology played an increasingly important role in the immune front, and made outstanding contributions to our country's early removal of the "hepatitis B power".
 
 
R & D innovation
 
 
Improving vaccine accessibility and affordability
 
 
 
Although the introduction of hepatitis B vaccine technology has brought significant social and economic benefits, Kangtai biological has not stopped here. A sustainable development road driven by continuous research and development innovation has become more and more clear in the growth process of Kangtai biological.
 
 
 
"The vaccine industry is a great event that benefits the country and the people, involving the happiness of generations. I want to make the Chinese people have access to advanced technology, low-cost, quality and safety vaccines. I can do this well in my life Du Weimin, chairman of Kangtai biology, said that he had been deeply involved in the vaccine industry for many years, and his original intention had not changed. "To achieve this goal, our vaccines should not only approach the international first-class level in terms of quality standards, but also complete the innovation leap on the basis of introduction and absorption."
 
In 2010, in the process of "introduction, absorption and innovation", Kangtai biological submitted the first answer sheet to improve the accessibility and affordability of vaccines. Since 2000, Kangtai biological Co., Ltd., after ten years of hard research and development, has launched a 60 microgram hepatitis B vaccine for low and unresponsive people with conventional hepatitis B vaccine. As the world's first variety, Kangtai biological has timely filled the market gap.
 
Starting from 60 micrograms of hepatitis B vaccine, Kangtai bio's quadruple vaccine, 23 valent pneumonia vaccine, leprosy vaccine, Hib vaccine and other new products have been launched. Among them, the quadruple vaccine is also the exclusive product initiated by the company, and it is the domestic combined vaccine with the largest number of combined vaccines. It can significantly improve the compliance of infant vaccination, obtain the major scientific and technological achievements of the national "863 special project", and have considerable competitive advantages in the market.
 
In addition, Kangtai biology also has more than 30 research projects, 12 of which have entered the registration process. 13 valent pneumococcal conjugate vaccine